Onychomycosis Market Size to Hit USD 6.41 Billion by 2035

What is the Onychomycosis Market Size in 2026?

The global onychomycosis market size was valued at USD 4.03 billion in 2025 and is projected to grow from USD 4.22 billion in 2026 to approximately USD 6.41 billion by 2035, expanding at a CAGR of 4.74% during the forecast period from 2026 to 2035.

The market is witnessing steady growth due to the rising prevalence of fungal nail infections, increasing cases of diabetes, and a growing geriatric population. Additionally, heightened awareness regarding personal hygiene and nail health is significantly boosting the demand for effective treatment solutions globally.

Read Also: Infant Resuscitators Market

Key Takeaways

• North America dominated the global market in 2025
• Asia-Pacific is expected to grow at the fastest CAGR through 2035
• By type, distal subungual onychomycosis led the market in 2025
• By type, white superficial onychomycosis is expected to grow fastest
• By treatment, topical treatments dominated the market in 2025
• By treatment, oral treatments are expected to expand at the highest CAGR

Market Overview

The onychomycosis market focuses on the development and commercialization of treatments for fungal nail infections affecting toenails and fingernails. These infections not only cause cosmetic concerns but also lead to discomfort, pain, and complications in severe cases.

The market is driven by increasing incidences of fungal infections worldwide, particularly among elderly and diabetic populations who are more susceptible due to weakened immunity. Furthermore, advancements in antifungal therapies and improved diagnostic tools are enhancing treatment success rates and patient compliance.

What Drives the Onychomycosis Market?

Several key factors are fueling market growth:

• Rising Prevalence of Diabetes: Diabetic patients are more prone to fungal infections, significantly increasing demand for treatments.
• Growing Geriatric Population: Aging individuals have reduced immunity, making them more susceptible to nail infections.
• Improved Awareness: Increased awareness about personal hygiene and nail care is driving early diagnosis and treatment.
• Advancements in Treatment Options: Development of advanced topical and oral antifungal drugs is improving treatment outcomes.
• Increased R&D Investments: Pharmaceutical companies are investing heavily in innovative drug formulations and delivery systems.

How is AI Influencing the Onychomycosis Market?

Artificial Intelligence (AI) is transforming the diagnosis and treatment of onychomycosis:

• AI-powered image analysis tools can accurately detect fungal infections using dermoscopic and microscopic images
• Machine learning models achieve high diagnostic accuracy, often surpassing traditional methods
• Mobile-based AI applications enable remote diagnosis, especially beneficial in underserved regions
• AI assists in personalized treatment recommendations by analyzing patient-specific data
• Predictive analytics helps monitor treatment response and identify potential complications

These advancements are enhancing early detection, improving treatment precision, and expanding access to care.

Key Market Trends

1. Rise of Advanced Topical Treatments

Innovative topical formulations such as nail lacquers and solutions with improved penetration are gaining popularity due to reduced side effects compared to oral medications.

2. Growth of OTC and E-commerce Channels

Over-the-counter availability and online distribution platforms are expanding market reach, especially in developed economies.

3. Increasing Adoption of Combination Therapies

Combination treatments involving oral drugs, topical solutions, and laser therapy are becoming common to improve efficacy and reduce recurrence.

4. Technological Advancements in Devices

Laser therapies and photodynamic treatments are emerging as effective non-invasive options, particularly for resistant infections.

5. Rising Demand from Elderly and Diabetic Population

A growing patient pool due to aging and diabetes continues to drive demand for advanced treatment solutions.

Future Market Outlook

The onychomycosis market is expected to present strong growth opportunities in the coming years:

• Expansion in emerging markets such as India, China, and Latin America
• Development of nanotechnology-based and sustained-release drug formulations
• Increased access to dermatology services due to healthcare infrastructure improvements
• Rising demand for minimally invasive and non-systemic treatments

Market Scope

Segmental Insights

Type Insights

Distal Subungual Onychomycosis

This segment dominated the market in 2025 due to its high prevalence. Pharmaceutical companies are focusing heavily on developing targeted therapies for this type, leading to increased treatment adoption.

White Superficial Onychomycosis

Expected to grow at the fastest CAGR, this type is easier to diagnose and treat with topical solutions, making it highly attractive for patients seeking non-invasive options.

Treatment Insights

Topical Segment

The topical segment led the market in 2025 due to:

• Lower risk of systemic side effects
• Ease of application
• Increased availability of OTC products
• Improved drug penetration technologies

Oral Segment

The oral segment is expected to grow rapidly due to:

• Higher effectiveness in treating severe infections
• Ability to penetrate deeper nail layers
• Higher cure rates compared to topical treatments

Regional Insights

North America

North America dominated the market in 2025 due to:

• High prevalence of fungal infections
• Advanced healthcare infrastructure
• Strong presence of pharmaceutical companies
• High healthcare expenditure

The U.S. remains a major contributor, driven by increasing awareness and continuous innovation in treatment options.

Asia-Pacific

Asia-Pacific is expected to grow at the fastest CAGR due to:

• Rising awareness of personal hygiene
• Increasing diabetic and elderly population
• Improving healthcare infrastructure
• Growing adoption of OTC antifungal products

Countries such as India and China are key growth engines in the region.

Europe

Europe is experiencing steady growth driven by:

• Increased focus on dermatology care
• Rising demand for advanced treatment solutions
• Growing awareness about early diagnosis

Latin America

Growth in Latin America is supported by:

• High infection rates due to humid climate
• Expanding access to dermatological treatments
• Increasing adoption of advanced therapies

Middle East & Africa

The market in this region is driven by:

• Favorable climatic conditions for fungal growth
• Rising awareness of hygiene and nail care
• Growing demand for non-invasive treatments

Competitive Landscape

Key companies operating in the onychomycosis market include:

• Bausch Health Companies Inc.
• Teva Pharmaceutical Industries Ltd.
• Cipla
• Merck & Co., Inc.
• GSK plc
• Abbott
• Pfizer Inc.
• Bayer AG
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Galderma Laboratories
• Moberg Pharma AB

These companies are focusing on product innovation, strategic partnerships, and geographic expansion to strengthen their market presence.

Recent Developments

• Moberg Pharma partnered with Karo Healthcare for the commercialization of MOB-015 across Europe
• Sato Pharmaceutical and Eisai ended their co-promotion agreement for antifungal treatments in Japan

Conclusion

The global onychomycosis market is poised for steady growth, driven by increasing infection rates, rising awareness, and advancements in treatment technologies. With the integration of AI, innovative drug formulations, and expanding healthcare infrastructure, the market is expected to witness significant transformation over the forecast period.

Get Sample Copy: https://www.precedenceresearch.com/sample/7920

For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com